A study conducted by researchers at Duke Health has found adalimumab — sold as Humira® — can be an effective treatment for patients suffering from noninfectious uveitis.
Researchers studied 217 adults with active, non-infectious intermediate or posterior uveitis, or panuveitis, analyzing their time to treatment failure. They reportedly found the median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group, and patients in the adalimumab group were significantly less likely to experience treatment failure during the duration of the study (80 weeks).
Humira is manufactured and marketed by pharmaceutical company AbbVie, who received approval from the U.S. Food and Drug Administration (FDA) for the treatment of non-infectious intermediate, posterior and panuveitis earlier this year.
Click here to read the full press release.